Shots:
- Genevant & Arbutus reached a global settlement with Moderna to resolve all US & international disputes over the alleged unauthorized use of their LNP delivery technology in the COVID-19 vaccines, incl. Spikevax
- As part of the settlement, Moderna will pay $950M upfront to Genevant & Arbutus in Jul 2026 & ~$1.3B more pending an appellate ruling on 28 U.S.C. § 1498, after conceding infringement & validity of four LNP patents
- Additionally, under the settlement, Genevant will grant Moderna a global non-exclusive license to its LNP delivery tech for infectious disease uses & provide a covenant not to sue over certain Genevant/Arbutus patents & related Moderna products
Ref: Roivant | Image: Moderna, Genevant & Arbutus | Press Release
Related News: Recordati and Moderna Collaborate To Develop And Commercialize mRNA 3927 in a ~$160M Deal
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
